Anti-Tumor Drugs Global Market Report 2025

Description

Anti-tumor drugs are medications aimed at preventing, inhibiting, or treating tumor growth, especially in cancer. They function by destroying cancer cells, halting their division, blocking growth-promoting signals, or activating the immune system to attack cancer cells. These drugs are commonly used alone or alongside surgery, radiation, or other treatments to enhance patient outcomes and lower the chances of cancer recurrence.

The primary categories of anti-tumor drugs include cytotoxic drugs, targeted therapies, hormonal therapies, immunotherapies, and others. Cytotoxic drugs specifically kill or damage cells and are mainly employed to destroy cancer cells by disrupting their growth and division. These medications treat various cancers such as lung, breast, colorectal, prostate, and more. They are administered via multiple routes, including oral and injectable forms, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The anti-tumor drugs market research report is one of a series of new reports from The Business Research Company that provides anti-tumor drugs market statistics, including anti-tumor drugs global market size, regional shares, competitors with anti-tumor drugs market share, detailed anti-tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-tumor drugs industry. The anti-tumor drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-tumor drugs market size has grown rapidly in recent years. It will grow from $186.18 billion in 2024 to $206.81 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. Growth during the historic period can be attributed to rising cancer incidence, increased adoption of targeted therapies and immunotherapies, a surge in clinical trials, expanded use of personalized medicine approaches, and higher healthcare spending.

The anti-tumor drugs market size is expected to see rapid growth in the next few years. It will grow to $311.86 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. Growth in the forecast period is expected to be driven by an increasing emphasis on precision medicine, a expanding pipeline of novel anti-tumor agents, rising demand for oral oncology drugs, greater penetration of anti-tumor drugs in emerging markets, and an increase in clinical trials targeting rare and refractory tumors. Key trends during this period include the development of bispecific antibodies for solid tumors, integration of genomic biomarkers in treatment planning, incorporation of companion diagnostics alongside drug launches, innovations in antibody-drug conjugates, and advancements in tumor microenvironment modulators.

The rising incidence of cancer is expected to drive growth in the anti-tumor drugs market moving forward. Cancer encompasses a group of diseases marked by the uncontrolled growth and spread of abnormal cells in the body, which can invade nearby tissues and potentially metastasize through the blood and lymphatic systems. The increase in cancer cases is mainly attributed to unhealthy lifestyle factors such as poor diet, physical inactivity, smoking, excessive alcohol use, and prolonged exposure to environmental pollutants, all of which significantly elevate the risk of developing various cancers. Anti-tumor drugs work by targeting and eliminating malignant cells, slowing tumor growth, and preventing disease progression. For example, in July 2024, the Australian Institute of Health and Welfare, an Australian government agency, reported that cancer diagnoses in Australia reached 160,570 cases in 2022, up by 3,789 from 156,781 cases in 2021. Consequently, the growing number of cancer cases is boosting the anti-tumor drug market.

Key players in the anti-tumor drugs market are concentrating on developing precision therapies, such as targeted treatments for breast cancer, to improve therapeutic outcomes in hormone receptor-positive metastatic cases. Targeted breast cancer treatments involve precision medicines that specifically interfere with cancer cell growth pathways, reducing harm to healthy cells and enhancing patient tolerance. For instance, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, introduced Palbociclib, a new anti-cancer drug in India for advanced breast cancer. Palbociclib is a selective oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial in regulating the cell cycle. By blocking the transition from the G1 phase to the S phase, this drug causes cell cycle arrest, thereby inhibiting tumor growth. It is mainly used for hormone receptor-positive, HER2-negative advanced breast cancer, targeting the uncontrolled proliferation of cancer cells.

In February 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired ImmunoGen for $10.1 billion. This acquisition aims to strengthen AbbVie's oncology portfolio, expand its pipeline of innovative cancer treatments, and reinforce its position in the global biopharmaceutical market. ImmunoGen, Inc., based in the US, is a biotechnology company specializing in anti-tumor drugs.

Major players in the anti-tumor drugs market are Pfizer Inc, Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG., GlaxoSmithKline plc, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Astellas Pharma Inc., Incyte Corporation, BeOne Medicines Inc., Getwell Oncology Pvt Ltd., Shanghai Haihe Pharmaceutical Co. Ltd.

North America was the largest region in the anti-tumor drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-tumor drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anti-tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-tumor drugs market consists of sales of opdevlimidivo, avastin, herceptin, and revlimid. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creatorsA of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Tumor Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-tumor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-tumor drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anti-tumor drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Type: Cytotoxic Drugs; Targeted Therapy Drugs; Hormonal Therapy Drugs; Immunotherapy Drugs; Other Drug Types
2) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Other Cancer Types
3) By Route of Administration: Oral; Injectable; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
Subsegments:
1) By Cytotoxic Drugs: Alkylating Agents; Antimetabolites; Plant Alkaloids; Antitumor Antibiotics; Other Cytotoxic Drugs
2) By Targeted Therapy Drugs: Monoclonal Antibodies; Tyrosine Kinase Inhibitors; Mechanistic Target Of Rapamycin Inhibitors; Poly Polymerase Inhibitors; Others Targeted Therapy Drugs
3) By Hormonal Therapy Drugs: Selective Estrogen Receptor Modulators; Aromatase Inhibitors; Luteinizing Hormone-Releasing Hormone Agonists; Anti-Androgens; Other Hormonal Therapy Drugs
4) By Immunotherapy Drugs: Checkpoint Inhibitors; Chimeric Antigen Receptor T-Cell Therapy; Cancer Vaccines; Cytokines; Other Immunotherapy Drugs
5) By Other Drug Types: Gene Therapy Drugs; Anti-Angiogenic Agents; Radioisotope-Based Drugs; Photodynamic Therapy Agents
Companies Mentioned: Pfizer Inc; Johnson And Johnson; Roche Holding AG; Merck And Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG.; GlaxoSmithKline plc; Eli Lilly And Company; Gilead Sciences Inc.; Amgen Inc.; Boehringer Ingelheim GmbH; Astellas Pharma Inc.; Incyte Corporation; BeOne Medicines Inc.; Getwell Oncology Pvt Ltd.; Shanghai Haihe Pharmaceutical Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r36926

1. Executive Summary

2. Anti-Tumor Drugs Market Characteristics

3. Anti-Tumor Drugs Market Trends And Strategies

4. Anti-Tumor Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Anti-Tumor Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Anti-Tumor Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Anti-Tumor Drugs Market Growth Rate Analysis
5.4. Global Anti-Tumor Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Anti-Tumor Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Anti-Tumor Drugs Total Addressable Market (TAM)

6. Anti-Tumor Drugs Market Segmentation

6.1. Global Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cytotoxic Drugs
Targeted Therapy Drugs
Hormonal Therapy Drugs
Immunotherapy Drugs
Other Drug Types
6.2. Global Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Other Cancer Types
6.3. Global Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Other Routes Of Administration
6.4. Global Anti-Tumor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.5. Global Anti-Tumor Drugs Market, Sub-Segmentation Of Cytotoxic Drugs, By Drug Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alkylating Agents
Antimetabolites
Plant Alkaloids
Antitumor Antibiotics
Other Cytotoxic Drugs
6.6. Global Anti-Tumor Drugs Market, Sub-Segmentation Of Targeted Therapy Drugs, By Drug Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Mechanistic Target Of Rapamycin Inhibitors
Poly Polymerase Inhibitors
Others Targeted Therapy Drugs
6.7. Global Anti-Tumor Drugs Market, Sub-Segmentation Of Hormonal Therapy Drugs, By Drug Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selective Estrogen Receptor Modulators
Aromatase Inhibitors
Luteinizing Hormone-Releasing Hormone Agonists
Anti-Androgens
Other Hormonal Therapy Drugs
6.8. Global Anti-Tumor Drugs Market, Sub-Segmentation Of Immunotherapy Drugs, By Drug Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Checkpoint Inhibitors
Chimeric Antigen Receptor T-Cell Therapy
Cancer Vaccines
Cytokines
Other Immunotherapy Drugs
6.9. Global Anti-Tumor Drugs Market, Sub-Segmentation Of Other Drug Types, By Drug Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gene Therapy Drugs
Anti-Angiogenic Agents
Radioisotope-Based Drugs
Photodynamic Therapy Agents

7. Anti-Tumor Drugs Market Regional And Country Analysis

7.1. Global Anti-Tumor Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Anti-Tumor Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-Tumor Drugs Market

8.1. Asia-Pacific Anti-Tumor Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-Tumor Drugs Market

9.1. China Anti-Tumor Drugs Market Overview
9.2. China Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-Tumor Drugs Market

10.1. India Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-Tumor Drugs Market

11.1. Japan Anti-Tumor Drugs Market Overview
11.2. Japan Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-Tumor Drugs Market

12.1. Australia Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-Tumor Drugs Market

13.1. Indonesia Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-Tumor Drugs Market

14.1. South Korea Anti-Tumor Drugs Market Overview
14.2. South Korea Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-Tumor Drugs Market

15.1. Western Europe Anti-Tumor Drugs Market Overview
15.2. Western Europe Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-Tumor Drugs Market

16.1. UK Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-Tumor Drugs Market

17.1. Germany Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-Tumor Drugs Market

18.1. France Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-Tumor Drugs Market

19.1. Italy Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-Tumor Drugs Market

20.1. Spain Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-Tumor Drugs Market

21.1. Eastern Europe Anti-Tumor Drugs Market Overview
21.2. Eastern Europe Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-Tumor Drugs Market

22.1. Russia Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-Tumor Drugs Market

23.1. North America Anti-Tumor Drugs Market Overview
23.2. North America Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-Tumor Drugs Market

24.1. USA Anti-Tumor Drugs Market Overview
24.2. USA Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-Tumor Drugs Market

25.1. Canada Anti-Tumor Drugs Market Overview
25.2. Canada Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-Tumor Drugs Market

26.1. South America Anti-Tumor Drugs Market Overview
26.2. South America Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-Tumor Drugs Market

27.1. Brazil Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-Tumor Drugs Market

28.1. Middle East Anti-Tumor Drugs Market Overview
28.2. Middle East Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-Tumor Drugs Market

29.1. Africa Anti-Tumor Drugs Market Overview
29.2. Africa Anti-Tumor Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Anti-Tumor Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Anti-Tumor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-Tumor Drugs Market Competitive Landscape And Company Profiles

30.1. Anti-Tumor Drugs Market Competitive Landscape
30.2. Anti-Tumor Drugs Market Company Profiles
- 30.2.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Anti-Tumor Drugs Market Other Major And Innovative Companies

31.1. Bayer AG
31.2. Sanofi S.A.
31.3. Bristol-Myers Squibb Company
31.4. AstraZeneca PLC
31.5. Novartis AG.
31.6. GlaxoSmithKline plc
31.7. Eli Lilly And Company
31.8. Gilead Sciences Inc.
31.9. Amgen Inc.
31.10. Boehringer Ingelheim GmbH
31.11. Astellas Pharma Inc.
31.12. Incyte Corporation
31.13. BeOne Medicines Inc.
31.14. Getwell Oncology Pvt Ltd.
31.15. Shanghai Haihe Pharmaceutical Co. Ltd.

32. Global Anti-Tumor Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Tumor Drugs Market

34. Recent Developments In The Anti-Tumor Drugs Market

35. Anti-Tumor Drugs Market High Potential Countries, Segments and Strategies

35.1 Anti-Tumor Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Anti-Tumor Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Anti-Tumor Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer